The role of serum ADAMTS-1 levels in Hyperemesis Gravidarum

Burcu Timur1* and Gurhan Guney2

Abstract

Background: We aimed to investigate the levels of ADAMTS-1, which is secreted from the extracellular matrix during trophoblastic invasion in hyperemesis gravidarum (HEG).

Methods: In this cross-sectional study, we compared 45 HEG patients aged between 21 and 34 in terms of ADAMTS-1 levels with a control group consisting of 44 healthy pregnant women. The demographic characteristics and several laboratory parameters of the patients were recorded. Both groups were also compared in terms of ketonuria. We evaluated the correlation between ADAMTS-1 levels and ketonuria.

Results: The 2 groups were matched in terms of age, gestational age, gravidity, parity, and body mass index. Some inflammatory markers, such as neutrophil count, MPV, PDW, and PCT levels, were significantly higher in the HEG groups compared to the control group (all \( p < 0.05 \)). However, mean MCV and serum TSH levels were statistically significantly lower in this group (both \( p < 0.001 \)). ADAMTS-1 levels were 12.6 ± 1.4 ng/ml in the HEG group and 6.2 ± 1.6 ng/ml in the control group (\( p < 0.001 \)). It was significantly and positively correlated with urine ketone, neutrophil count, and PDW, whereas negatively correlated with MCV and TSH value in the HEG group. ROC analysis showed that a threshold value of 11.275 ng/ml for ADAMTS-1 predicted HEG patients with a sensitivity of 60% and specificity of 95.5%.

Conclusion: ADAMTS-1 serum levels are increased in HEG patients, and there is a positive correlation between ADAMTS-1 levels and ketonuria.

Keywords: Hyperemesis gravidarum, ADAMTS-1 protein, Ketosis, Pregnancy, Placenta

Background

Hyperemesis gravidarum (HEG), representing the severe end of the spectrum associated with nausea and vomiting in pregnancy, refers to persistent vomiting resulting in ketonuria and/or ketonemia leading to weight loss and volume reduction exceeding 5% of pre-pregnancy weight [1]. HEG, which occurs in about two percent of all pregnancies in the United States, may cause the pregnant woman to be unable to do her daily work, lead to anxiety and depression, compel some patients to terminate the pregnancy, and avoid planning future pregnancies [2]. In addition to its negative effects on the mother, it is also associated with poor fetal outcomes, such as preterm birth, neuronal developmental delay, and embryopathy due to vitamin K deficiency [3]. HEG is the most common reason for hospitalization in the first trimester of pregnancy, and it has an economic burden on the health system [4, 5].

HEG is not observed in every patient with high hCG values. In the studies, it was stated that different isoforms and/or different receptors of hCG and their interactions with other molecules secreted in the extracellular environment may be responsible for the difference in hyperemesis symptoms, but no clear result has
ADAMTS-1 was originally identified in a cachexia model and cachexia has overlapping symptoms with HEG (appetite loss, weight loss, and muscle wasting) [11]. Therefore, we aimed to confirm whether if ADAMTS-1 has a role in the development of HEG. Moreover, the relationship between ADAMTS-1 and other biochemical parameters known to be associated with HEG were investigated.

Methods
This study was approved by the Gumushane University Ethics Committee (Project number: 2022/E-95674917) and was conducted in accordance with the Declaration of Helsinki. All participants included in the study gave written and verbal informed consent prior to being enrolled in the study.

Patients
In this cross-sectional study, the HEG group consisted of 45 patients aged between 21 and 34 who were admitted for nausea and vomiting during pregnancy to the Ordu University Education and Research Hospital Gynecology and Obstetrics Clinic between January 2018 and January 2022. The control group consisted of 44 pregnant women who applied to the same clinic for routine antenatal follow up and were matched in terms of chronological age, gestational age, and body mass index (BMI). Patients with diabetes or obesity, peptic ulcer or gastritis, liver and/or gallbladder disease (cholangitis or gallstones), thyroid dysfunction, urinary tract infection, coeliac disease, cardiovascular or renal diseases were excluded from our study. We also excluded any patients who has nausea and vomiting and any patients who has threatened miscarriage, as vaginal bleeding during pregnancy may affect ADAMTS levels [12]. Multiple pregnancies and/or pregnancies obtained by assisted reproductive techniques, gestational trophoblastic disease, and autoimmune disease conditions were also not included in the study.

HEG was diagnosed if there was a persistent vomiting resulting in ketonuria and/or ketonemia leading to weight loss and volume reduction exceeding 5% of pre-pregnancy weight.

Women who vomited more than 3 times a day due to HEG and/or who had a positive urine ketone test result and/or were hospitalized for HEG 2 or more times. BMI was measured by dividing the weight in kilograms by the height in meters squared (kg/m²). Doctors performed the first transabdominal pregnancy ultrasonography using a 3.5 MHz transabdominal transducer (General Electric Logiq A5 ultrasound machine, Milwaukee, USA), and the gestational age was estimated according to the first trimester ultrasonographic value of fetal crown-rump length.

Laboratory studies
All laboratory analyses for each patient were performed in the early morning after an overnight fast of 8–12 h. We first hydrated the patients with 1000 cc RL solution and collected serum samples after sufficient urine output. We did not dilute the serum samples.

We evaluated complete blood count, thyroid-stimulating hormone (TSH), T3, T4, fasting plasma glucose, BMI, aspartate transferase, alanine transferase (ALT), blood urea nitrogen (BUN), and creatinine levels.

Measurement of serum ADAMTS-1 Levels
Venous blood samples were collected from each participant’s antecubital vein after at least 8 h of fasting and
then separated by centrifugation at 4000 rpm for 10 min. In order to measure serum ADAMTS-1 protease, we obtained blood samples after we diagnosed HEG and then we stored the materials at -80 °C until the study time. Frozen serum samples were thawed to room temperature and were not diluted. ADAMTS-1 levels were measured with a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Hangzhou Eastbiopharm Co., Ltd., China) and this ELISA kit was specific for ADAMTS-1. The test procedure was completed in accordance with the manufacturer’s instructions using biotin double-antibody sandwich technology. Serum samples were added onto wells that were previously coated with ADAMTS-1 monoclonal antibodies. Biotin labelled anti-ADAMTS-1 antibodies and streptavidin-HRP were added to form immune complexes. Following incubation, unbound enzymes were removed by washing. Chromogen solutions A and B were then added. Stop solution was used to stop the reaction and formed yellow color’s optical density was measured by using a microplate reader at 450 nm, which was proportional to the amount of ADAMTS-1. ADAMTS-1 serum levels, as ng/ml, were interpolated from a standard curve. The intra-and interassay variation coefficients of the kit were smaller than 9% and 11%, respectively.

Statistical analyses
Statistical analysis was performed using SPSS version 22. Descriptive statistics, such as mean, standard deviation, and median (minimum–maximum), were used while statistically defining normal and non-normal variables. Normality was tested using the Shapiro–Wilk test. After performing the normality test, parametric (independent samples t-test) and non-parametric (Mann–Whitney U) analysis tests were used to detect the differences between the groups. Spearman’s rank-order correlation method was used for univariate correlations. To reveal the predictive value of ADAMTS-1 protein for HEG, the receiver operator characteristics curve (ROC) analysis was applied. A priori power analysis for the two independent means was done using G*Power software (Universität Kiel, Kiel, Germany) to define an adequate sample size with a large effect size (α: 0.05 and β: 0.95). We considered p value less than 0.05 as statistically significant.

Results
In our current cross-sectional study, we compared 45 HEG patients with a control group consisting of 44 healthy pregnant women without nausea and vomiting caused by pregnancy. Table 1 shows the demographics and clinical characteristics of both groups. There was no difference between the two groups in terms of age (26.5 ± 5 vs. 28.5 ± 6, p:0.084), gestational week

| **Table 1** Demographics and clinical characteristics of the groups |
| **Variable** | **HEG (n:45)** | **CONTROL (n::44)** | **P** |
|--------------|----------------|---------------------|------|
| Age(years)   | 26.5 ± 5       | 25.2 ± 6            | 0.084|
| Gravida      | 2 ± 1.5        | 2 ± 2               | 0.515|
| Pancy        | 0 ± 1          | 1 ± 1               | 0.188|
| No of Living Child | 0 ± 1 | 1 ± 1 | 0.150|
| No of Abortion | 0 ± 1 | 0 ± 0 | 0.373|
| Gestational weeks | 8 ± 1.4 | 9 ± 5.1 | 0.904|
| BMI (kg/m²)  | 23.9 ± 3.8     | 25.3 ± 3.7          | 0.086|

Data presented as Mean ± SD
P<0.05 accepted as significant

| **Table 2** Laboratory parameters of the groups |
| **Variable** | **HEG (n:45)** | **CONTROL (n::44)** | **P** |
|--------------|----------------|---------------------|------|
| Urine ketone | 80 ± 55(40–150)| 0                   | <0.001|
| Blood glucose | 96.4 ± 26.5 | 90.3 ± 10.0        | 0.154|
| BUN          | 21.4 ± 6.7     | 19.0 ± 5.6          | 0.069|
| Creatinine   | 0.6 ± 0.1      | 0.6 ± 0.1           | 0.693|
| AST          | 249.4 ± 29.0   | 206.4 ± 48          | 0.342|
| ALT          | 265.5 ± 37.6   | 161.1 ± 11.1        | 0.086|
| WBC          | 8.6 ± 2.3      | 8.9 ± 1.7           | 0.576|
| Neutrophile  | 74.4 ± 7.5     | 68.1 ± 9.2          | 0.001|
| Lymphocyte   | 23.1 ± 6.3     | 223.7 ± 5.7         | 0.051|
| Monocyte     | 5.3 ± 1.8      | 7.1 ± 6.6           | 0.093|
| Hb           | 13.3 ± 1.1     | 13.1 ± 1.2          | 0.211|
| Hct          | 38.7 ± 3.0     | 38.6 ± 2.8          | 0.882|
| MCV          | 82.7 ± 5.7     | 85.6 ± 5.9          | 0.020|
| RDW          | 14.0 ± 2.7     | 145.3 ± 3.2         | 0.417|
| PLT          | 268.2 ± 72.3   | 257.1 ± 62.3        | 0.437|
| MPV          | 10.0 ± 1.4     | 8.8 ± 1.0           | <0.001|
| PCT          | 0.26 ± 0.06    | 0.22 ± 0.05         | 0.003|
| PDW          | 16.0 ± 0.5     | 14.4 ± 0.4          | 0.002|
| Free T3      | 3.3 ± 0.9      | 3.1 ± 0.3           | 0.135|
| Free T4      | 1.2 ± 0.5      | 1.0 ± 0.2           | 0.001|
| TSH          | 0.9 ± 0.7      | 1.6 ± 1.2           | 0.001|
| ADAMTS-1     | 12.6 ± 3.6     | 6.2 ± 1.4           | <0.001|

(8.1 ± 4.8 vs. 9.0 ± 5.1 weeks, p:0.904), gravidia (2 ± 1.5 vs. 2.1 ± 2, p:0.505), and BMI (24.0 ± 3.8 vs. 25.3 ± 3.7, p:0.086). Table 2 shows the biochemical characteristics of both groups. There was an insignificant difference between the two groups in terms of hemoglobin, hematocrit, platelet, AST, ALT, BUN, creatinine, and fasting glucose values (all p>0.05). When compared with the control group, MPV (10.0 ± 1.4 fl vs. 8.8 ± 1.0 fl), PCT (0.26 ± 0.06 vs. 0.22 ± 0.05), PDW (16.0 ± 0.5 vs. 14.4 ± 0.4), and free T4 (1.2 ± 0.5 ng/dl vs. 1.0 ± 0.2 ng/dl) values were significantly higher (p<0.001, p:0.003, p:0.002, and p:0.001, respectively), while the MCV
(82.7 ± 5.7 fl vs. 85.6 ± 5.9 fl) and TSH (0.9 ± 0.7 mU/l vs. 1.6 ± 1.2 mU/l) values were significantly lower in HEG group (p:0.020 and p:0.001, respectively). Urine ketone levels were significantly higher in HEG group than in the control group. We also observed that ADAMTS-1 levels were significantly higher in the HEG group compared to the control group (12.6 ± 3.6 ng/dl vs. 6.2 ± 1.4 ng/dl, p < 0.001).

Spearman’s rank-order correlation also showed that ADAMTS-1 levels were significantly and positively correlated with urine ketone, neutrophil count, PDW, and free T4 levels, whereas they were negatively correlated with MCV and TSH values in the HEG group (Table 3).

The ROC analysis showed that the area under the ROC curve (AUC) was 0.731 (0.619–0.843, 95% confidence interval). This means that ADAMTS-1 is a useful biomarker for distinguishing pregnant women diagnosed with HEG (p < 0.001). The cut-off value according to the highest Youden’s index was calculated to be 11.275 ng/ml for ADAMTS-1 with a sensitivity of 60% and specificity of 95.5% (Fig. 1).

Discussion
In this study, we showed that serum ADAMTS-1 levels were significantly increased in HEG patients compared with the healthy pregnant control group. There was a significant and positive correlation with urine ketone levels and a significant negative correlation with serum TSH levels. Our study is the first to evaluate ADAMTS-1 levels in HEG patients and their associations with other biochemical parameters.
Liu et al. [13] stated in their study that not only hCG but also many different cytokines are secreted from trophoblasts in chorionic villi, and hCG alone may not be responsible for nausea and vomiting. For example, in a study by Fezio M.S et al. [14] it was found that the GDF-15 gene encodes a TGF-β superfamily member, which is expressed at high levels in the trophoblast cells of the placenta, and this protein, which has high levels in maternal blood especially in the first two trimesters, acts to facilitate placentation and suppress pro-inflammatory production of cytokines in order to suppress the continuation of pregnancy. In addition to this role, in the same study, it was shown that GDF 15 activates hypothalamic neurons and regulates body weight and appetite by affecting the nausea-vomiting center in the area postrema. In a study conducted by Kuno et al. [11] and Lerner L et al. [15], which included the same model of cachexia, they showed that overproduction of GDF-15 in cancer patients was the main cause of cancer anorexia and cachexia, and it led to the symptoms of chronic nausea and vomiting in HEG. They also found that ADAMTS-1 and GDF-15 together may be associated with cancer cachexia. Thus, in the future it will be interesting to determine whether ADAMTS-1 increases GDF15 levels or vice versa. It has been shown in various studies that the presence of ADAMTS-1 is needed for a healthy implantation, placentation, and continuation of pregnancy [10, 16, 17]. In a large population-based cohort study, it was reported that the incidence of small-for-gestational age (SGA) increased in women with HEG [18]. It has been claimed that this may be secondary to placentation abnormality and stated that this possibility is stronger in the presence of HEG and early-onset preeclampsia, especially in the second trimester [18]. In the literature, there is no study investigating the relationship between ADAMTS-1 levels and HEG, but there was a study investigating its levels in preeclampsia patients. In this study by Kalem et al. [9], the ADAMTS-1 levels in the blood of preeclamptic patients were lower, and the levels in the placental tissue were higher than in the control group. In our study, we found ADAMTS-1 levels to be significantly higher in HEG patients than in the control group. Based on this, crosstalk between trophoblasts and the extracellular matrix might be correlated with ADAMTS-1 levels rather than trophoblast invasion in HEG. It is well known that ADAMTS-1 functions as a VEGF antagonist [19]. VEGF, on the other hand, is a vascular permeability factor that plays a role in angiogenesis, which is produced in the maternal fetal unit at high levels and secreted into the maternal blood during pregnancy. Schreurs et al. [20] showed that VEGF had the feature of increasing the blood–brain barrier. In a different study, Miyata et al. [21] showed that the blood–brain barrier, which is more permeable than other parts of the brain as formed by fenestrated capillaries, could become more permeable with VEGF, especially in circumventricular organs such as the area postrema, which includes the nausea and vomiting center inside. Despite the relationship mentioned above, we could not find any study investigating VEGF levels in patients with HEG. Therefore, based on the above studies, we thought that ADAMTS-1 levels, which are high in HEG patients, might be secreted from the placenta as a compensation mechanism to regulate the increased permeability in the nausea-vomiting center. In a small number of studies on ADAMTS-1, it has been shown that by regulating the blood–brain barrier, it enables neurons to adapt to the new situation [22]. Although higher levels of ADAMTS-1 as an VEGF antagonist, would hypothetically result in decreased permeability which should decrease nausea and vomiting, ADAMTS-1 antagonizes VEGF to regulate trophoblastic invasion at the receptor level in the placenta. Considering that the VEGF receptor types in placental and neural tissues are different, it is possible that ADAMTS-1 may not be effective on VEGF receptors in the brain, or GDF-15 or some other growth factors and or cytokines may reduce the activity of ADAMTS-1 [10, 23].

It is well known that ketone bodies are a fuel for the brain as an alternative to glucose in long periods of fasting and have the ability to cross the blood–brain barrier [24]. Studies have shown that starvation ketosis could be observed in long-term nausea and vomiting seen in HEG, and this might be harmful to the maternal and fetal neuronal system [25]. ADAMTS-1 might have a function, such as protecting the blood–brain barrier from the negative effects of ketone bodies, because ADAMTS-1 is an antagonist of VEGF, which increases the blood–brain barrier. Although most studies could not find a relationship between ketonuria and HEG severity, we detected a significant degree of ketonuria in our HEG group compared to the control group, and we observed a positive correlation between ketonuria and ADAMTS-1 levels [26]. In a different study that investigated the relation between ketonuria and HEG, Soysal et al. [27] claimed that ketonuria in HEG was determined by the inflammatory response in pregnancy rather than HEG itself. Similar to that study, we found that inflammatory markers such as PDW, PCT, and MPV were higher in the HEG group compared with the control group.

One of the main weaknesses of this study is that GDF 15 levels were not measured. Another weakness is that we did not measure VEGF levels as there was no standardized value in the first trimester of pregnancy. The well-matched features of the patients and the fact that they were free from the effects of BMI and age showed that the results and comparisons were reliable.
Conclusions
This study was the first clinical study to measure ADAMTS-1 levels in HEG patients. ADAMTS-1 levels were higher in HEG patients and positively correlated with ketonuria in this group of patients. Further comprehensive studies including the relationship of ADAMTS-1 with more patients in HEG and its relation with GDF-15 are recommended to reveal a clearer understanding of this subject.

Abbreviations
ADAMTS-1: A disintegrin and metalloproteinase with thrombospondin motifs 1; HEG: Hyperemesis gravidarum; MPV: Mean platelet volume; PDW: Platelet distribution width; PCT: Plateletcrit; MMP: Matrix metalloproteinases; ROC: Receiver operating characteristic; BMI: Body mass index; TSH: Thyroid stimulating hormone.

Acknowledgements
We would like to thank all patients who agreed to participate in this study.

Human rights statements and informed consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from all patients for inclusion in the study.

Authors’ contributions
BT: Conceptualization, Investigation, Methodology, Formal Analysis, Writing – Original Draft Preparation, Review and Editing. GG: Formal Analysis, Software, Supervision, Writing – Review and Editing. The author(s) read and approved the final manuscript.

Funding
No funding.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The Ethics Committee of Gumushane University approved our study (Project number:2022/E-95674917).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Obstetrics and Gynecology, Ordu University Training and Research Hospital, Bucak District, Nefu Bucak Street, Ordu 52200, Turkey.
2 Department of Obstetrics and Gynecology, Balkesir University Medical Faculty, Balkesir, Turkey.

Received: 15 April 2022  Accepted: 10 June 2022
Published online: 20 June 2022

References
1. Jennings LK, Mahdy H. Hyperemesis Gravidarum. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022, PMID: 30422512, Bookshelf ID: NBKS532917.
2. Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2018;31(18):2492–505.
3. Fejzo MS, Magtria A, Schoenberg FP, Macgibbon K, Mullin PM. Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 2015;189:79–84.
4. London V, Grube S, Sheer DM, Abulafia O. Hyperemesis gravidarum: a review of recent literature. Pharmacology. 2017;100(3–4):161–71.
5. Trovik J, Vikanes Å. Hyperemesis Gravidarum is associated with substantial economic burden in addition to severe physical and psychological suffering. ISRN Health Policy Res. 2016;5345.
6. Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8:102.
7. Lockhart SM, Saudek V, O’Rahilly S. GDF15: a hormone conveying somatic distress to the Brain. Endocr Rev. 2020;41(4):bnaa007.
8. Fejzo MS, Macgibbon KW, First O, Quan C, Mullin PM. Whole-exome sequencing uncovers new variants in GDF15 associated with hyperemesis gravidarum. Bjog. 2022. https://doi.org/10.1111/1471-0528.17129. Online ahead of print.
9. Namli Kalem M, Kalem Z, Yuce T, Soylemez F. ADAMTS 1, 4, 12, and 13 levels in maternal blood, cord blood, and placenta in preeclampsia. Hypertens Pregnancy. 2018;37(1):9–17.
10. Lee SY, Lee HS, Gil M, Kim CJ, Lee YH, Kim KR, et al. Differential expression patterns of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) -1, -4, -5, and -14 in human placenta and gestational trophoblastic diseases. Arch Pathol Lab Med. 2014;138(5):643–50.
11. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem. 1997;272(1):556–62.
12. Pekcan MK, Sankaya E, Tokmak A, Alşık M, Alkan A, Özakşit G, et al. ADAMTS-3, -13, -16, and -19 levels in patients with habitual abortion. Kaohsiung J Med Sci. 2017;33(1):30–5.
13. Liu C, Zhao G, Qiao D, Wang L, He Y, Zhao M, et al. Emerging progress in nausea and vomiting of pregnancy and hyperemesis gravidarum: challenges and opportunities. Front Med (Lauzanne). 2021;8:809270.
14. Fejzo MS, Sazonova OV, Sathirapongsasuti JF, Hallgrímsdóttir IB, Vacic V, Macgibbon KW, et al. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat Commun. 2018;9(1):1178.
15. Lerner I, Tao J, Liu Q, Nicolotti R, Feng B, Krieger B, et al. MAP3K11/GDF15 axis is a critical driver of cancer cachexia. J Cachexia Sarcopenia Muscle. 2016;7(4):467–82.
16. Ng YH, Zhu H, Pallen CJ, Leung PC, Macalman CD. Differential effects of interleukin-1beta and transforming growth factor-beta1 on the expression of the inflammation-associated protein, ADAMTS-1, in human decidual stromal cells in vitro. Hum Reprod. 2006;21(8):1990–9.
17. Mishra B, Koshi K, Kazuki K, Ushizawa K, Takahashi T, Hosoe M, et al. Expression of ADAMTS1 mRNA in bovine endometrium and placenta during gestation. Domest Anim Endocrinol. 2013;45(1):43–8.
18. Bolin M, Åkerud H, Cnattingius S, Stephansson O, Wikström AK. Hyperemesis gravidarum and risks of placental dysfunction disorders: a population-based cohort study. BJOG. 2013;120(5):541–7.
19. Hismiogullar AA, Guney G, Ismey Taksan K, Gungor M, et al. Expression of ADAMTS1 mRNA in bovine endometrium and placenta during gestation. J Reprod Med. 2014;59(9):390.
20. Schreurs MP, Houston EM, May V, Cipolla MJ. The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy. Faseb J. 2012;26(1):355–62.
21. Miyata S. New aspects in fenestrated capillary and tissue dynamics in the sensory circumventricular organs of adult brains. Front Neurosci. 2015;9:390.
22. Gottschall PE, Howell MD. ADAMTS expression and function in central nervous system injury and disorders. Matrix Biol. 2015;44:46–70–6.
23. Wittko-Schneider IM, Schneider FT, Plate KH. Brain homeostasis: VEGF receptor 1 and 2—two unequal brothers in mind. Cell Mol Life Sci. 2015;72(4):390.
25. Qian M, Wu N, Li L, Yu W, Ouyang H, Liu X, et al. Effect of elevated ketone body on maternal and infant outcome of pregnant women with abnormal glucose metabolism during pregnancy. Diabetes Metab Syndr Obes. 2020;13:4581–8.

26. Koot MH, Grooten LJ, Post J, Bais JMI, Ris-Stalpers C, Naaktgeboren CA, et al. Ketonuria is not associated with hyperemesis gravidarum disease severity. Eur J Obstet Gynecol Reprod Biol. 2020;254:315–20.

27. Soysal C, Işıkalan MM, Bıyık İ, Erten Ö, Ince O. The relationship between inflammation markers and ketonuria in hyperemesis gravidarum. J Obstet Gynaecol Res. 2021;47(9):3078–83.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.